In a 35-day study in children aged 5 to 12, no tolerance to the antihistaminic effect (suppression of wheal and flare) of cetirizine was found. When a treatment with cetirizine is stopped after repeated administration, the skin recovers its normal reactivity to histamine within 3 days. Instances of abnormal hepatic function with elevated hepatic enzymes accompanied by elevated bilirubin have been reported. Mostly this resolves upon discontinuation of the treatment with cetirizine dihydrochloride. Cetirizine is excreted in human milk at concentrations representing 25% to 90% of those measured in plasma, depending on sampling time after administration. Therefore, caution should be exercised when prescribing cetirizine to lactating women.

GALPHARM HAYFEVER AND ALLERGY RELIEF, WILKO HAYFEVER

History of hypersensitivity to any of the constituents of the formulation, to hydroxyzine or to any piperazine derivatives.Studies in healthy volunteers show that cetirizine, at doses of 5 and 10 mg strongly inhibits the wheal and flare reactions induced by very high concentrations of histamine into the skin, but the correlation with efficacy is not established. Giving you relief for up to 24 hours, Galpharm Hay fever and Allergy Relief tablets help to soothe common hay fever symptoms: such as itchy or watery eyes, sneezing and a runny nose. These long-lasting hay fever tablets also stop symptoms from other allergies e.g. pet, house dust mite and mould spore allergies. What is an allergy? At therapeutic doses, no clinically significant interactions have been demonstrated with alcohol (for a blood alcohol level of 0.5g/L). Nevertheless, precaution is recommended if alcohol is taken concomitantly.

Galpharm - Savers Galpharm - Savers

Undesirable effects are described according to MedDRA System Organ Class and by estimated frequency based on post-marketing experience. Very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to 1/100); rare (> 1/10,000 to 1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data)Patients with moderate to severe renal impairment: there are no data to document the efficacy/safety ratio in patients with renal impairment. Since cetirizine is mainly excreted via renal route (see section 5.2), in cases no alternative treatment can be used, the dosing intervals must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient’s cre­atinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula: The distribution of pharmacokinetic parameters such as peak plasma concentration (Cmax) and area under curve (AUC), is unimodal in human volunteers. The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased. The extent of bioavailability is similar when cetirizine is given as solutions, capsules or tablets.